NCT07057024Active, not recruiting
Contribution of Virtual Reality Eye Tracking in the Identification of Schizophrenia, Bipolar and Depression
Source: ClinicalTrials.gov · Last updated 6 Mar 2026
Brief summary (registry, in English)
Schizophrenia (SCZ), bipolar disorder (BP), and depression (DEP) are systematically associated with a severe impairment of the overall abilities of patients, which precludes them from functioning adequately in daily life. A large body of literature emphasises the importance of identifying specific markers for these pathologies to prevent or anticipate the emergence of new psychopathological symptoms. As a result, one of the current research challenges is to develop new, faster, and more reliable tools. Eye movements are physiological signs involving brain areas that control cognitive processes. These same processes could be altered in psychiatric disorders, and these alterations could produce many eye movement abnormalities. The literature highlights some eye movement abnormalities specific to each targeted pathology. However, to our knowledge, no study has compared eye movement abnormalities in a virtual environment projected in a head-mounted display (HMD). The investigators hypothesised that an eye tracker connected to an HMD could identify specific eye movement abnormalities of SCZ, BP, and DEP. Recording eye movements specific to these pathologies in pseudo-ecological situations could lead to better identification methods.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 30 Dec 2024
- Start date
- 12 Feb 2026
- Primary completion date
- Feb 2028
- Lead sponsor
- Etablissement Public de Santé Barthélemy Durand
- Diseases
- Schizophrenia, Bipolar disorder
- NCT number
- NCT07057024
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 12 Feb 2026 to the primary completion date, Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or previous psychiatric disorder
- Current psychotropic drug therapy
Other illness
- Current(s) somatic(s) condition(s)
- Epilepsy history
Other
- For all the participants :
- Subjects unable to give consent or not volunteering for the study.
- Specific ophthalmological problems (strabismus, amblyopia) incompatible with the devices stereoscopic (VR headsets)
- Head trauma's history with loss of consciousness
- Intellectual disability
- Difficulties in understanding the French language
- Current or during the last 6 months of substance abuse or dependence (except tobacco)
- Freedom restriction by judicial or administrative decision and/or coercive hospitalisation
- Cybersickness history
- Pregnancy
- For healthy control group :
Who the study is looking for
- For all participants:
- Male or female, aged 18 to 60 years
- Subject having given their written consent to the study For Schizophrenia participants :
- Diagnosis of schizophrenia according to DSM-V criteria and stabilised for at least three months
- For bipolar disorder participants :
- \- Diagnosis of bipolar disorders according to DSM-V criteria and stabilised for at least three months
- For depressive disorders participants :
- \- Diagnosis of depressive disorders according to DSM-V criteria and stabilised for at least three months
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Etablissement Public de Santé Barthélemy Durand Coordinator of this site? Confirm its status | Étampes | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.